Boost Your Energy and Reverse the Symptoms of Menopause! Rachel’s Story

by | Jul 11, 2013


A green chalkboard with the message 'I LOVE YOU' written in white chalk.
At age 49, my patient Rachel felt like she was falling apart. She had suffered a tragic stress a few years earlier, from which she was still struggling to recover. Now, in addition, she was beginning to experience Perimenopause. She had absolutely no energy, was cold all the time, had vaginal dryness and zero sex drive, felt weak and shaky if she skipped a meal, had gained 15+ pounds in the last year or two. was developing cellulite in her thighs, buttocks and arms and was experiencing heart palpitations. She felt anxious, depressed, irritable, mentally dull and was losing her short term memory.

She had taken Ambien and Valium for the stress and poor sleep in the past, but they didn’t fix her problems and made her feel even more sluggish. She needed a doctor who would look at the whole picture of her health. She needed a doctor who would prescribe a comprehensive treatment that would address all of her symptoms and treat the underlying bio-chemical causes of those symptoms. That’s what I do. That is what Naturopathic Medicine is all about: treating the whole person with medicines made by nature that work in harmony with the body to stimulate the positive actions required to restore truly dynamic health.
Top 5 Lifestyle Causes of Fatigue

  1. Lack of Sleep
  2. Stress
  3. Poor Diet
  4. Lack of Exercise
  5. Drugs (Beta Blockers)

Top 5 Tests for Bio-Chemical Causes of Fatigue

  1. CBC Test for Anemia (Iron or B12 Deficiency)
  2. Thyroid hormones(TSH, freeT3, freeT4)
  3. Adrenal Hormones: Cortisol, Aldosterone, Adrenaline, Norepnephrine & Dopamine
  4. CoEnzymeQ10 (B2, B3, B5, B6, B12, Folic Acid, Vitamin C)
  5. Total Testosterone Bio-Available Testosterone Blood Test

 A green chalkboard with the message 'I LOVE YOU' written in white chalk.

p
A green chalkboard with the message 'I LOVE YOU' written in white chalk.
After my comprehensive visit with Rachel I was confident that Rachel had multi-system, multi-gland dysfunction. Her stress level and the typical decline in hormones around Perimenopause had caused her to hormones to take an unusually rapid decline. The best way to treat a multi-glandular dysfunction is to treat all of them at once. When all of the hormone secreting glands are treated at the same time, it is like a well tuned orchestra coming together again after a long absence. Together they create a powerful resonating melody that cannot be matched by any one of them individually. Likewise, when all of the hormones are supplemented together, they resonate as one dynamic whole to bring about incredible energy and optimal health and vitality.
So how did Rachel do on the Bio-Identical Hormone Treatment? After one month she returned to report that she was “feeling great! She said, “it is a totally incredible difference. I am so happy now. I’m no longer irritable all of the time and I have so much more energy now, including my sex drive, which is incredible. Plus, I’m sleeping great, I can get up early in the morning, stay up all day and I get all my house work done. My kids can tell a huge difference. They are so glad that their Mom is finally back! Its an amazing difference and it feels great.”

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

14 + 6 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });